Failed renoprotection by alternatively activated bone marrow macrophages is due to a proliferation-dependent phenotype switch in vivo

Kidney International

Volumn 85, Issue 4, 2014, Pages 794-806

  Cao, Qi ^a   Wang, Yiping ^a   Zheng, Dong ^a   Sun, Yan ^b   Wang, Changqi ^a   Wang, Xin M ^a   Lee, Vincent W S ^a   Wang, Ya ^a   Zheng, Guoping ^a   Tan, Thian K ^a   Wang, Yuan M ^c   Alexander, Stephen I ^c   Harris, David C H ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^c CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

Adriamycin nephropathy; Alternatively activated macrophages; Bone marrow M2; Phenotype stability

Indexed keywords

COLONY STIMULATING FACTOR 1; MESSENGER RNA; DOXORUBICIN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CELL PROLIFERATION; CELL TRANSFER; CONTROLLED STUDY; FUNCTIONAL ASSESSMENT; GENE EXPRESSION; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY STRUCTURE; MACROPHAGE; MACROPHAGE ACTIVATION; MACROPHAGE FUNCTION; MALE; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; TREATMENT FAILURE; KIDNEY INJURY; KIDNEY TUBULE CELL; M2 MACROPHAGE; NEPHRITIS; SPLEEN CELL; ANIMAL; BAGG ALBINO MOUSE; CHEMICALLY INDUCED; COMPARATIVE STUDY; CYTOLOGY; IMMUNOLOGY; KIDNEY DISEASES; KIDNEY TUBULE; METABOLISM; PHYSIOLOGY; SPLEEN; TRANSPLANTATION;

ADOPTIVE TRANSFER; ANIMALS; BONE MARROW CELLS; CELL PROLIFERATION; DOXORUBICIN; KIDNEY DISEASES; KIDNEY TUBULES; MACROPHAGE COLONY-STIMULATING FACTOR; MACROPHAGES; MALE; MICE, INBRED BALB C; PHENOTYPE; SPLEEN;

EID: 84897375257     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.341     Document Type: Article

References (56)

1. Eddy AA. Progression in chronic kidney disease. Adv Chronic Kidney Dis 2005; 12: 353-365.
2. Teteris SA, Engel DR, Kurts C. Homeostatic and pathogenic role of renal dendritic cells. Kidney Int 2011; 80: 139-145.
3. Anders HJ, Muruve DA. The inflammasomes in kidney disease. J Am Soc Nephrol 2011; 22: 1007-1018.
4. Reynolds J, Prodromidi EI, Juggapah JK et al. Nasal administration of recombinant rat alpha3(IV)NC1 prevents the development of experimental autoimmune glomerulonephritis in the WKY rat. J Am Soc Nephrol 2005; 16: 1350-1359.
5. Heymann F, Meyer-Schwesinger C, Hamilton-Williams EE et al. Kidney dendritic cell activation is required for progression of renal disease in a mouse model of glomerular injury. J Clin Invest 2009; 119: 1286-1297.
6. Cao Q, Wang C, Zheng D et al. IL-25 induces M2 macrophages and reduces renal injury in proteinuric kidney disease. J Am Soc Nephrol 2011; 22: 1229-1239.
7. Graves DT, Kayal RA. Diabetic complications and dysregulated innate immunity. Front Biosci 2008; 13: 1227-1239.
8. Ricardo SD, van Goor H, Eddy AA. Macrophage diversity in renal injury and repair. J Clin Invest 2008; 118: 3522-3530.
9. Nelson PJ, Rees AJ, Griffin MD et al. The renal mononuclear phagocytic system. J Am Soc Nephrol 2012; 23: 194-203.
10. Sean Eardley K, Cockwell P. Macrophages and progressive tubulointerstitial disease. Kidney Int 2005; 68: 437-455.
11. Vernon MA, Mylonas KJ, Hughes J. Macrophages and renal fibrosis. Semin Nephrol 2010; 30: 302-317.
12. Anders HJ, Ryu M. Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis. Kidney Int 2011; 80: 915-925.
13. Lee S, Huen S, Nishio H et al. Distinct macrophage phenotypes contribute to kidney injury and repair. J Am Soc Nephrol 2011; 22: 317-326.
14. Wang Y, Wang Y, Cao Q et al. By homing to the kidney, activated macrophages potently exacerbate renal injury. Am J Pathol 2008; 172: 1491-1499.
15. Rodriguez Guerrero A, Uchida K, Nakajima H et al. Blockade of interleukin-6 signaling inhibits the classic pathway and promotes an alternative pathway of macrophage activation after spinal cord injury in mice. J Neuroinflammation 2012; 9: 40.
16. Marchetti V, Yanes O, Aguilar E et al. Differential macrophage polarization promotes tissue remodeling and repair in a model of ischemic retinopathy. Sci Rep 2011; 1: 76.
17. Sica A, Mantovani A. Macrophage plasticity and polarization: In vivo veritas. J Clin Invest 2012; 122: 787-795.
18. Wang Y, Wang YP, Zheng G et al. Ex vivo programmed macrophages ameliorate experimental chronic inflammatory renal disease. Kidney Int 2007; 72: 290-299.
19. Cao Q, Wang Y, Zheng D et al. IL-10/TGF-beta-modified macrophages induce regulatory T cells and protect against adriamycin nephrosis. J Am Soc Nephrol 2010; 21: 933-942.
20. Cao Q, Zheng D, Wang YP et al. Macrophages and dendritic cells for treating kidney disease. Nephron Exp Nephrol 2011; 117: E47-e52.
21. Wang Y, Harris DC. Macrophages in renal disease. J Am Soc Nephrol 2011; 22: 21-27.
22. Molony DA, Stephens BW. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: Therapeutic considerations. Adv Chronic Kidney Dis 2011; 18: 120-131.
23. Zheng D, Wang Y, Cao Q et al. Transfused macrophages ameliorate pancreatic and renal injury in murine diabetes mellitus. Nephron Exp Nephrol 2011; 118: E87-e99.
24. Mantovani A, Sica A, Sozzani S et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004; 25: 677-686.
25. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006; 354: 610-621.
26. Vielhauer V, Anders HJ. Chemokines and chemokine receptors as therapeutic targets in chronic kidney disease. Front Biosci (Schol Ed) 2009; 1: 1-12.
27. Thomson AW, Robbins PD. Tolerogenic dendritic cells for autoimmune disease and transplantation. Ann Rheum Dis 2008; 67: Iii90-iii96.
28. Kavousanaki M, Makrigiannakis A, Boumpas D et al. Novel role of plasmacytoid dendritic cells in humans: Induction of interleukin-10-producing Treg cells by plasmacytoid dendritic cells in patients with rheumatoid arthritis responding to therapy. Arthritis Rheum 2010; 62: 53-63.
29. Kalantari T, Kamali-Sarvestani E, Ciric B et al. Generation of immunogenic and tolerogenic clinical-grade dendritic cells. Immunol Res 2011; 51: 153-160.
30. Stoop JN, Robinson JH, Hilkens CM. Developing tolerogenic dendritic cell therapy for rheumatoid arthritis: What can we learn from mouse models?. Ann Rheum Dis 2011; 70: 1526-1533.
31. Terabe M, Ambrosino E, Takaku S et al. Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-Transforming growth factor-beta monoclonal antibody. Clin Cancer Res 2009; 15: 6560-6569.
32. O'Neill DW, Adams S, Bhardwaj N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 2004; 104: 2235-2246.
33. Tang S, Moore ML, Grayson JM et al. Increased CD8+ T cell function following castration and immunization is countered by parallel expansion of regulatory T cells. Cancer Res 2012; 72: 1975-1985 .
34. Palucka K, Ueno H, Banchereau J. Recent developments in cancer vaccines. J Immunol 2011; 186: 1325-1331.
35. Movahedi K, Guilliams M, Van den Bossche J et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008; 111: 4233-4244.
36. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5: 263-274.
37. Gabrilovich D. Mechanisms and functional significance of tumourinduced dendritic-cell defects. Nat Rev Immunol 2004; 4: 941-952.
38. Michielsen AJ, Hogan AE, Marry J et al. Tumour tissue microenvironment can inhibit dendritic cell maturation in colorectal cancer. PLoS One 2011; 6: E27944.
39. Kryczek I, Banerjee M, Cheng P et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009; 114: 1141-1149.
40. Norian LA, Rodriguez PC, O'Mara LA et al. Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-Arginine metabolism. Cancer Res 2009; 69: 3086-3094.
41. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 2007; 117: 1155-1166.
42. Ferenbach DA, Ramdas V, Spencer N et al. Macrophages expressing heme oxygenase-1 improve renal function in ischemia/reperfusion injury. Mol Ther 2010; 18: 1706-1713.
43. Sapi E, Flick MB, Rodov S et al. Expression of CSF-I and CSF-I receptor by normal lactating mammary epithelial cells. J Soc Gynecol Investig 1998; 5: 94-101.
44. Stanley ER, Cifone M, Heard PM et al. Factors regulating macrophage production and growth: Identity of colony-stimulating factor and macrophage growth factor. J Exp Med 1976; 143: 631-647.
45. Menke J, Kriegsmann J, Schimanski CC et al. Autocrine CSF-1 and CSF-1 receptor coexpression promotes renal cell carcinoma growth. Cancer Res 2012; 72: 187-200.
46. Wilson SE, Mohan RR, Netto M et al. RANK, RANKL, OPG, and M-CSF expression in stromal cells during corneal wound healing. Invest Ophthalmol Vis Sci 2004; 45: 2201-2211.
47. Moore KJ, Yeh K, Naito T et al. TNF-Alpha enhances colony-stimulating factor-1-induced macrophage accumulation in autoimmune renal disease. J Immunol 1996; 157: 427-432.
48. Menke J, Iwata Y, Rabacal WA et al. CSF-1 signals directly to renal tubular epithelial cells to mediate repair in mice. J Clin Invest 2009; 119: 2330-2342.
49. Jang MH, Herber DM, Jiang X et al. Distinct in vivo roles of colonystimulating factor-1 isoforms in renal inflammation. J Immunol 2006; 177: 4055-4063.
50. Hume DA, MacDonald KP. Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood 2012; 119: 1810-1820.
51. Racoosin EL, Swanson JA. Macrophage colony-stimulating factor (rM-CSF) stimulates pinocytosis in bone marrow-derived macrophages. J Exp Med 1989; 170: 1635-1648.
52. Cao Q, Wang L, Du F et al. Downregulation of CD4+CD25+ regulatory T cells may underlie enhanced Th1 immunity caused by immunization with activated autologous T cells. Cell Res 2007; 17: 627-637.
53. Lassailly F, Griessinger E, Bonnet D. 'Microenvironmental contaminations' induced by fluorescent lipophilic dyes used for noninvasive in vitro and in vivo cell tracking. Blood 2010; 115: 5347-5354.
54. Quah BJ, Warren HS, Parish CR. Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester. Nat Protoc 2007; 2: 2049-2056.
55. Kruger T, Benke D, Eitner F et al. Identification and functional characterization of dendritic cells in the healthy murine kidney and in experimental glomerulonephritis. J Am Soc Nephrol 2004; 15: 613-621.
56. Rangan GK, Tesch GH. Quantification of renal pathology by image analysis. Nephrology (Carlton) 2007; 12: 553-558.